Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
Related Questions
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
Would you expect cinacalcet to lower calcium levels in a patient with Familial Hypocalciuric Hypercalcemia (FHH)?
Do oral contraceptives lower bone mineral density in women with hypothalamic amenorrhea by lowering IGF-1?
Do you recommend osteoporosis medication in postmenopausal females on anastrozole with very low Vitamin D (4.5)?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Does biotin interfere with the measurement of other metabolites of the Vitamin D pathway outside of the 25-hydroxy Vitamin D assay?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
